ArticleFrontiers in oncology2025
Low expression of SOD and PRX4 as indicators of poor prognosis and systemic inflammation in colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Commentary: Low expression of SOD and PRX4 as indicators of poor prognosis and systemic inflammation in colorectal cancer.Frontiers in oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Oxidative stress, characterized by an imbalance between the levels of reactive oxygen species (ROS) and antioxidants, plays a critical role in cancer progression. However, the prognostic significance of antioxidant markers in colorectal cancer (CRC) remains unclear. This study aimed to evaluate the expression of antioxidant markers in tumor tissues and investigate their association with clinicopathological features, survival, and systemic inflammation. Methods: We retrospectively analyzed 70 patients with CRC who underwent curative surgical resection. The tissue levels of superoxide dismutase (SOD), glutathione peroxidase (GPx), peroxiredoxin 4 (PRX4), and thioredoxin (Trx) were measured in freshly frozen tissues, and the patients were classified into high and low expression groups using the 1st quartile as the cutoff. Associations between antioxidant levels in tumor tissue using ELISA and clinicopathological characteristics, laboratory inflammatory markers, and survival outcomes were analyzed. Results: Low SOD expression was significantly associated with a higher incidence of distant metastases. Similarly, low PRX4 expression was correlated with more aggressive tumor characteristics, including higher rates of distant metastasis, poor differentiation, and advanced T4 stage. Moreover, low PRX4 levels were linked to systemic inflammation, as reflected by increased neutrophil counts and neutrophil-lymphocyte ratio. Although not statistically significant, the low SOD and PRX4 groups exhibited worse 5-year disease-free survival. Conclusions: Low SOD and PRX4 expression was associated with aggressive tumor features, poor survival, and heightened systemic inflammation in patients with CRC. Given their association with tumor aggressiveness and systemic inflammation, antioxidant markers such as SOD and PRX4 may serve as supportive prognostic biomarkers to help identify patients at risk of adverse clinical outcomes in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.